agoniste glp 1 GLP-1 Receptor Agonists as Treatments for Type 2 Diabetes Trends in the Development of

Schwartz 2012

Key findings for semaglutide duration include continued weight loss through at least 68 weeks with no plateau in many patients, weight regain of approximately 40% of lost weight within seven months of stopping, and withdrawal effects including increased appetite, food cravings, and in some cases gastrointestinal changes

doi: 10.1210/mend-5-12-1806

November 2022

The aggregation-induced color change provides a platform for colorimetric assays, and the AuNP-based colorimetric method is applied to recognize and quantify some chiral molecules [14,15,16,17,18,19,20,21,22]

Maridebart cafraglutide (MariTide) is a combined GLP-1 receptor agonist and GIP receptor antagonist